-Demonstrates 95% Negative Predictive Value (NPV) in a Population with High Malignancy Rate; Confirms High NPV Shown in Earlier Reveal Validation Study

-Results Highlighted in Oral Presentation at the 3rd World Congress on Thyroid Cancer

PHILADELPHIA, PA and REHOVOT, ISRAEL / ACCESSWIRE / July 31, 2017 / Rosetta Genomics Ltd. (NASDAQ: ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, announces that data highlighting the integration of the RosettaGX Reveal™ (Reveal) into clinical practice was presented in an Oral Presentation at the 3rd World Congress on Thyroid Cancer on July 30, 2017. The Reveal microRNA classifier is a first-of-its-kind assay offering testing from a routinely prepared cytology slide that analyzes the exact cells used to make the original indeterminate diagnosis.

The oral presentation titled, “Incorporating the RosettaGX Reveal™ assay into clinical practice can significantly reduce the number of unnecessary surgeries associated with Indeterminate Thyroid Nodules (ITNs,)” was delivered by Nicole Massoll, M.D., Lab and Medical Director of Rosetta Genomics.

The presentation reviewed data on more than 1800 of the first patients tested with Reveal and demonstrated a high benign classification rate, which is important because the vast majority of ITNs are benign. Reveal was developed to identify these benign cases and help avoid unnecessary surgeries.

In addition, the presentation covered the results of a new survey of the use of Reveal in the clinical setting. The survey included responses from 40 physicians from 34 medical centers who utilize the Reveal assay in their clinical practices and reviewed their experience from 371 patients as it related to impact on patient management, decision to send patients to surgery or the extent of surgery, ease-of-use and overall feedback.

The survey results suggested that Reveal prevents unnecessary surgeries. In the pre-molecular era, the rate of surgery for ITNs was 74% [1]and the rate of surgery in this survey was 30.5%. In addition, 91% of the physicians who participated in the survey stated that Reveal changed the way they managed their patients with ITNs; 73% predicted that Reveal will decrease the number of patients sent to surgery; and 85% of patients with Reveal Benign results were able to avoid surgery.

Importantly, Reveal’s performance in those cases from the survey in which there was surgical outcome demonstrated a negative predictive value (NPV) of 95% in a setting with a relatively high prevalence of malignancy (35%). In addition, respondents gave a high rating on the assay’s ease-of-use, particularly as Reveal is performed from a routinely prepared cytology smear or ThinPrep slide. Unlike other molecular tests, Reveal analyzes the exact cells used to make the indeterminate cytology diagnosis, without the need for additional passes, repeat FNA procedures, refrigeration or special shipping.

“We are delighted to have presented these compelling data suggesting that Reveal can prevent unnecessary surgeries for patients with an ITN before an audience of expert physicians that are dedicated to improving the diagnosis and treatment of thyroid cancer,” stated Dr. Massoll. “These survey responses provide real world clinical experience in support of incorporating Reveal into clinical practice where it has shown to be a useful tool for further classification of ITNs with high sensitivity and high NPV even in settings where there is a high prevalence of thyroid cancer. Reveal’s high NPV can give physicians the confidence to rely on a benign test result, thus allowing them to observe their patients in lieu of taking them to surgery. These results are similar to the results from Reveal’s clinical validation study, further confirming the assay’s high NPV.”

“The positive results from this survey of physicians utilizing Reveal in real-world clinical practice are very encouraging and further support our strategy to increase our focus and investment in expanding the commercial, promotional and reimbursement efforts for Reveal to accelerate this differentiated product’s growth. Data such as these provide a solid building block for our team in developing a compelling value proposition for the integration of Reveal in clinical practice as well as for gaining increased coverage by payers,” said Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. “Reveal’s high NPV and ability to analyze the exact cells that were used to make the original ITN diagnosis are significant competitive advantages over other molecular ITN assays, which we expect will drive Reveal’s adoption in ITN classification. We continue to believe that Reveal offers a significant opportunity for both short- and long-term revenue growth and these positive data support that thesis.”

About Rosetta Genomics

Rosetta is pioneering the field of molecular diagnostics by offering rapid and accurate diagnostic information that enables physicians to make more timely and informed treatment decisions to improve patient care. Rosetta has developed a portfolio of unique diagnostic solutions for Endocrinologists, Cytopathologists, Otolaryngologists, Oncologists, and other specialists to help them deliver better care to their patients. RosettaGX Reveal™, a Thyroid microRNA Classifier for the evaluation of cancer in thyroid nodules, as well as the full RosettaGX™ portfolio of cancer testing services are commercially available through the Company’s Philadelphia, PA- and Lake Forest, CA-based CAP-accredited, CLIA-certified labs.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta’s future expectations, plans and prospects including, but not limited to statements relating to increasing our focus and investment in expanding the commercial, promotional and reimbursement efforts for Reveal to accelerate this differentiated product’s growth, developing a compelling value proposition for the integration of RosettaGX Reveal in clinical practice as well as for gaining increased coverage by payers, Reveal offering a significant opportunity for both short- and long-term revenue growth, driving Reveal’s adoption in ITN classification and statements containing the words “expect,” “believe,” “will,” “may,” “should,” “project,” “estimate,” “anticipated,” “scheduled,” and like expressions, and the negative thereof, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various risks and uncertainties, including, but are not limited to the following: we will require substantial additional funds to continue our operations and, if additional funds are not available, we may need to significantly scale back or cease our operations; we have a history of losses and may never be profitable; if we are unable to expand sales of our diagnostic tests in the United States, it would have a material adverse effect on our business and financial condition; if we are unable to find profitable strategic alternatives for our PersonalizeDx diagnostic testing and services business, it would have a material adverse effect on our business and financial condition; the intensely competitive biotechnology market could diminish demand for our tests and products; the market may not be receptive to any diagnostic tests or therapeutic products using our microRNA technology; we currently have limited sales, marketing or distribution experience and may in the future depend significantly on third parties to commercialize microRNA-based diagnostic tests or therapeutic products we may develop; we are largely dependent upon our distributors for the success of commercialization of our current diagnostic tests; health insurers and other third-party payers may decide not to cover our diagnostic products or may provide inadequate reimbursement, which could jeopardize our commercial prospects; because of Medicare billing rules, we may not receive reimbursement for all tests provided to Medicare patients; if we fail to comply with our obligations under any licenses or related agreements, we could lose license rights that may be necessary for developing microRNA-based diagnostics and therapeutics; if we fail to comply with the complex federal, state, local and foreign laws and regulations that apply to our business, we could suffer severe consequences that could materially and adversely affect our operating results and financial condition; we contract with a single manufacturer for the purchase of microarray chips for certain tests, and the failure of this manufacturer to supply sufficient quantities on a timely basis could have a material adverse effect on our business; and other risk factors discussed under the heading “Risk Factors” in Rosetta’s most recently filed Annual Report on Form 20-F, as filed with the SEC. In addition, any forward-looking statements represent Rosetta’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Various statements in this release concerning Rosetta’s future expectations, plans and prospects constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the “Risk Factors” section of Rosetta’s most recently filed Annual Report on Form 20-F, as filed with the SEC. In addition, any forward-looking statements represent Rosetta’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Rosetta Genomics Contact: Rosetta Genomics Investor Contact:

Rosetta Genomics Contact:

Ken Berlin, President & CEO
(267) 298-1159
investors@rosettagx.com

Rosetta Genomics Investor Contact:

LHA
Anne Marie Fields
(212) 838-3777
afields@lhai.com

[1] Duick DS, et al. Thyroid (2012)

SOURCE: Rosetta Genomics Ltd.

ReleaseID: 470069

Research Desk Line-up: Graco Post Earnings Coverage

LONDON, UK / ACCESSWIRE / July 31, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Lennox International Inc. (NYSE: LII) (“Lennox”), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=LII, following the Company’s reporting of its second quarter fiscal 2017 earnings results on July 24, 2017. The manufacturer of furnaces, air conditioners, and other products outperformed top- and bottom-line expectations. Lennox also raised its lower-end earnings and revenue guidance for FY17. Our daily stock reports are accessible for free, and with those to look forward today you also will be signing up for a complimentary member’s account at:

http://protraderdaily.com/register/

Get more of our free earnings reports coverage from other constituents of the Diversified Machinery industry. Pro-TD has currently selected Graco Inc. (NYSE: GGG) for due-diligence and potential coverage as the Company announced on July 26, 2017, its financial results for Q2 and six months which ended on June 30, 2017. Register for a free membership today, and be among the early birds that get access to our report on Graco when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on LII; also brushing on GGG. With the links below you can directly download the report of your stock of interest free of charge at:

http://protraderdaily.com/optin/?symbol=LII

http://protraderdaily.com/optin/?symbol=GGG

Earnings Reviewed

For the three months ended June 30, 2017, Lennox reported record revenue of $1.10 billion, up 8% compared to revenue of $1.02 billion in Q2 2016, led by 14% residential growth. The Company’s volume increased, while rice/mix was flat on a revenue basis. Lennox’s revenue numbers surpassed analysts’ expectations of $1.09 billion.

For Q2 2017, Lennox’s gross profit totaled $341 million, up 8% compared to $315.0 million in Q2 2016. The Company’s gross profit was positively impacted by higher volume, favorable price/mix, and sourcing and engineering-led cost reductions, with offsets from higher commodity costs, investments in distribution expansion, and foreign exchange. Lennox’s gross margin was flat at 30.9%

On a GAAP basis, Lennox’s income from continuing operations for Q2 2017 was $116.4 million, or $2.71 per share, compared to $111.2 million, or $2.52 per share, in Q2 2016. The Company’s earnings from continuing operations for the reported quarter included net after-tax charges of $4.6 million. Lennox’s adjusted income from continuing operations in Q2 2017 was $121.0 million, or $2.83 per share, compared to $111.5 million, or $2.53 per share, in the prior year’s corresponding quarter. The Company’s earnings numbers exceeded Wall Street’s expectations of $2.76 per share.

Segment Details

During Q2 2017, Lennox’s Residential Heating & Cooling business segment’s revenue rose 14% to a record $654 million. This segment’s profit for the reported quarter surged 21% to a record $141 million. The segment’s profit margin expanded 130 basis points to a record 21.5%. Results were impacted by higher volume, favorable price/mix, sourcing, and engineering-led cost reductions, and favorable warranty, and other product costs.

Lennox’s Q2 2017 revenue from the Commercial Heating & Cooling business segment was a record $259 million, up 2% on a y-o-y basis. The segment’s revenue grew 3% on a y-o-y basis. This segment’s margin was down 140 basis points to 17.3%, and the segment’s profit declined 6% to $45 million. Results were impacted by unfavorable mix, higher commodity costs, investments in research and development, information technology, and other selling, general, and administrative expenses (SG&A), partially offset by included higher volume, sourcing and engineering-led cost reductions, and favorable price.

For Q2 2017, Lennox’s Refrigeration business segment generated revenue of $190 million, down 1% on a y-o-y basis. This segment’s margin expanded 30 basis points to 11.4% in the reported quarter, and this segment’s profit rose 1% to $22 million. Results were impacted by favorable price/mix and sourcing and engineering-led cost reductions, with partial offsets from factory productivity, investments in research and development, information technology, and other SG&A.

Cash Matters

Lennox’s net cash from operations in Q2 2017 was $59 million compared to $76 million in Q2 2016. The Company’s capital expenditures for the reported totaled $18 million, flat on a y-o-y basis. For Q2 2017, Lennox’s free cash flow was $41 million compared to $58 million in the prior-year’s same quarter.

As the end of Q2 2017, the Company’s total debt was $1.19 billion. Total cash and cash equivalents were $61 million as of June 30, 2017. In Q2 2017, Lennox paid $18 million in dividends and $100 million for stock repurchases.

Outlook

For FY17, Lennox raised the low-end of its guidance for revenue and adjusted EPS from continuing operations.

For FY17, Lennox is forecasting revenue growth in the range of 4% to 7% from the previous forecast of 3% to 7%. The Company expects a minimal impact from foreign exchange.

Lennox narrowed its GAAP EPS from continuing operations projections from $7.65-$8.25 to $7.73-$8.13, while it also raised the low-end of its adjusted EPS from continuing operations guidance from $7.55-$8.15 to $7.75-$8.15. Lennox is estimating corporate expenses of approximately $85 million and capital expenditures of approximately $100 million.

Stock Performance

On Friday, July 28, 2017, the stock closed the trading session at $171.02, slightly falling 0.62% from its previous closing price of $172.09. A total volume of 370.00 thousand shares have exchanged hands, which was higher than the 3-month average volume of 353.26 thousand shares. Lennox’s stock price advanced 3.40% in the last three months, 9.09% in the past six months, and 7.58% in the previous twelve months. Furthermore, since the start of the year, shares of the Company have rallied 11.65%. The stock is trading at a PE ratio of 24.51 and has a dividend yield of 1.19%. At Friday’s closing price, the stock’s net capitalization stands at $7.26 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 470037

Research Desk Line-up: Colfax Post Earnings Coverage

LONDON, UK / ACCESSWIRE / July 31, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Illinois Tool Works Inc. (NYSE: ITW) (“ITW”), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=ITW, following the Company’s announcement of its financial results on July 24, 2017, for Q2 FY17. The Company reported GAAP EPS increase of 16% y-o-y, and a revenue increase of 4.9% y-o-y with an operating margin of 24.3%, an increase of 120 bps y-o-y which is an all-time record for the Company. Our daily stock reports are accessible for free, and with those to look forward today you also will be signing up for a complimentary member’s account at:

http://protraderdaily.com/register/

Get more of our free earnings reports coverage from other constituents of the Diversified Machinery industry. Pro-TD has currently selected Colfax Corporation (NYSE: CFX) for due-diligence and potential coverage as the Company announced on July 28, 2017, its financial results for Q2 2017. Register for a free membership today, and be among the early birds that get access to our report on Colfax when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on ITW; also brushing on CFX. With the links below you can directly download the report of your stock of interest free of charge at:

http://protraderdaily.com/optin/?symbol=ITW

http://protraderdaily.com/optin/?symbol=CFX

Earnings Reviewed

ITW generated operating revenues of $3.60 billion for Q2 FY17 compared to $3.43 billion for Q2 FY16, noting y-o-y increase of 4.9% y-o-y. The Company’s revenue numbers met analysts’ estimations of $3.60 billion. ITW noted that foreign currency translation reduced revenue by 1.2% in the reported quarter.

The Company’s operating income for Q2 FY17 was $874 million compared to $792 million for Q2 FY16, an increase of 10.35% y-o-y and was the highest quarterly income total in the Company’s history.

Net income for Q2 FY17 was $587 million compared to $525 million in Q2 FY16, an increase of 11.8% y-o-y. ITW’s net income per share in Q2 FY17 was $1.69 diluted compared to $1.46 diluted, an increase of 15.7% y-o-y. Excluding a $0.03 per share benefit from a legal settlement ITW’s EPS came in at $1.66, which was ahead of Wall Street’s forecasts of $1.63. The Company also enhanced its total current assets in Q2 FY17 to $6.57 billion compared to $6.12 billion in Q2 FY16, an increase of 7.35% y-o-y.

Segment Information

In Q2 FY17, ITW’s Automotive OEM division’s revenue surged 22.2% to $820 million; operating income of $182 million’ and operating margin of 22.3%, down 350 basis points (bps).

In the Food Equipment segment, the Company recorded total revenues of $529 million, down 1.4% on a y-o-y basis; while its operating income came in at $139 million and operating margin was 26.4% in Q2 FY17, up 140 bps on a y-o-y basis.

ITW’s Test & Measurement and Electronics division reported total revenues of $519 million, representing growth of 2.55 on a y-o-y basis; operating income of $114 million; and operating margin of 21.9% in Q2 FY17, surging 330 bps compared to the year ago same period.

In its Welding division, ITW generated total revenues of $385 million, up 2.9% on a y-o-y basis, while it recorded operating income of $105 million and operating margin of 27.2 % in Q2 FY17; adding 230 bps.

In its Polymers & Fluids, ITW generated total revenues of $437 million, down 1.3%; operating income of $94 million; and operating margin of 21.4% in Q2 FY17, up 50 bps. ITW’s Construction Products segment generated total revenues of $425 million, up 0.4%; operating income of $102 million; and operating margin of 24.0% in Q2 FY17, down 30 bps.

The Company’s Specialty Products segment generated total revenues of $490 million, adding 1.1%; operating income of $139 million; and operating margin of 28.3% in Q2 FY17, increasing 230 bps on a y-o-y basis.

Cash Matters

In Q2 FY17, ITW reported net cash provided by operating activities of $464 million compared to $535 million in Q2 FY16, a decrease of 13.27% y-o-y. The Company also noted free cash flow of $387 million in Q2 FY17 compared to $471 million in Q2 FY16; a decrease of 17.83% y-o-y.

ITW also reported free cash flow to net income conversion rate of 66% for Q2 FY17 compared to 90% in Q2 FY16. The Company, however, noted that excluding $115 million related to an additional discretionary pension contribution, the free cash flow to net income conversion rate for Q2 FY17 would have been 85%. Considering the pension contribution, the Company noted an adjusted free cash flow of $502 million in Q2 FY17.

Outlook

ITW raised its 2017 full-year EPS guidance by $0.12 at the midpoint based on its strong Q2 FY17 results. Now, the Company expects earnings to be in the range of $6.32 to $6.52 per share, up from its prior guidance of $6.20 to $6.40 per share, with organic revenue growth of 2% to 4%. ITW expects operating margin of approximately 24% and free cash flow to exceed 100% of net income. The Company projects an effective tax rate of approximately 29%. For the third quarter of 2017, the Company expects earnings to be in the range of $1.57 to $1.67 per share with organic growth of 1% to 3%.

Stock Performance

Illinois Tool Works’ share price finished last Friday’s trading session at $140.83, marginally advancing 0.01%. A total volume of 1.31 million shares have exchanged hands, which was higher than the 3-month average volume of 1.20 million shares. The Company’s stock price surged 1.98% in the last three months, 9.29% in the past six months, and 22.08% in the previous twelve months. Additionally, the stock gained 15.00% since the start of the year. Shares of the Company have a PE ratio of 22.80 and have a dividend yield of 1.85%. The stock currently has a market cap of $48.65 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 470034

Research Desk Line-up: JAKKS Pacific Post Earnings Coverage

LONDON, UK / ACCESSWIRE / July 31, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Hasbro, Inc. (NASDAQ: HAS), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=HAS, following the Company’s release of its second quarter fiscal 2017 earnings results on July 24, 2017. The No. 2 US toymaker outperformed earnings estimates. Our daily stock reports are accessible for free, and with those to look forward today you also will be signing up for a complimentary member’s account at:

http://protraderdaily.com/register/

Get more of our free earnings reports coverage from other constituents of the industry. Pro-TD has currently selected JAKKS Pacific, Inc. (NASDAQ: JAKK) for due-diligence and potential coverage as the Company reported on July 25, 2017, its financial results for Q2 2017 which ended on June 30, 2017. Register for a free membership today, and be among the early birds that get access to our report on JAKKS Pacific when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on HAS; also brushing on JAKK. With the links below you can directly download the report of your stock of interest free of charge at:

http://protraderdaily.com/optin/?symbol=HAS

http://protraderdaily.com/optin/?symbol=JAKK

Earnings Reviewed

For the quarter ended July 02, 2017, Hasbro’s net revenues increased 11% to $972.5 million versus $878.9 million in Q2 2016. The Company’s revenue numbers fell marginally short of analysts’ expectations of $973 million.

For Q2 2017, Hasbro reported Selling, Distribution, and Administration expenses (SD&A) of $256.90 million compared to $238.64 million in Q2 2016. The Company’s operating profit for the reported quarter totaled $99.98 million, or 10.3% of revenue, compared to $84.87 million, or 9.7% of revenue, in the prior year’s same quarter.

Hasbro’s net earnings for Q2 2017 surged 30% to $67.7 million, or $0.53 per diluted share, compared to $52.1 million, or $0.41 per diluted share, in 2016. The Pawtucket, Rhode Island-based Company’s reported net earnings included a $0.01 per diluted share benefit from the adoption of FASB ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting. Hasbro’s earnings numbers exceeded Wall Street’s estimates of $0.46 per share.

Segment Results

During Q2 2017, Hasbro’s US and Canada segment’s net revenues increased 16% to $494.4 million compared to $425.9 million in Q2 2016. The Company’s revenues grew in Franchise Brands, Partner Brands, and Hasbro Gaming, but declined in Emerging Brands. The US and Canada segment’s operating profit soared 41% to $81.6 million, or 16.5% of net revenues, in the reported quarter versus $58.0 million, or 13.6% of net revenues, in the prior year’s comparable quarter.

Hasbro’s International segment’s net revenues increased 6% to $426.6 million compared with revenue of $401.1 million in Q2 2016. The International segment’s revenues included a favorable $2.4 million impact of foreign exchange. Revenue growth in Franchise Brands and Hasbro Gaming offset declines in Partner Brands and Emerging Brands. On a regional basis, Europe revenues increased 4%, Latin America increased 3%, and Asia/Pacific increased 18% compared to their respective year ago performance. International segment’s operating profit decreased 43% to $16.9 million, or 4.0% of net revenues, compared to $29.7 million, or 7.4% of net revenues, in the year ago corresponding period.

During Q2 2017, Hasbro’s Entertainment and Licensing segment’s net revenues fell 1% to $51.5 million compared to $51.9 million in Q2 2016. Growth in digital gaming, led by Backflip Studios, was offset by declines in entertainment revenues. The Entertainment and Licensing segment’s operating profit dropped 18% to $11.3 million, or 22.0% of net revenues, compared to $13.8 million, or 26.6% of net revenues, in the year earlier same quarter.

Dividend and Share Repurchase

As of July 02, 2017, Hasbro’s cash and cash equivalents totaled $1.43 billion compared to $924.10 million as on June 26, 2016. The Company’s long-term debt at the end of the reported quarter was $1.20 billion. During Q2 2017, Hasbro generated cash flow from operating activities worth $366.11 million compared to $305.94 million in Q2 2016.

During Q2 2017, Hasbro paid $71.3 million in cash dividends to shareholders. The Company’s next quarterly cash dividend payment of $0.57 per common share is scheduled for August 15, 2017, to shareholders of record at the close of business on August 01, 2017.

In Q2 2017, Hasbro repurchased 6,100 shares of common stock at a total cost of $0.6 million and an average price of $94.99 per share. At quarter-end, $309.4 million remained available in the current share repurchase authorization.

Stock Performance

Hasbro’s share price finished last Friday’s trading session at $105.74, slightly sliding 0.84%. A total volume of 1.31 million shares have exchanged hands, which was higher than the 3-month average volume of 891.90 thousand shares. The Company’s stock price soared 6.69% in the last three months, 28.03% in the past six months, and 30.56% in the previous twelve months. Additionally, the stock skyrocketed 35.93% since the start of the year. Shares of the Company have a PE ratio of 22.85 and have a dividend yield of 2.16%. The stock currently has a market cap of $13.33 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 470033

Research Desk Line-up: Automatic Data Processing Post Earnings Coverage

LONDON, UK / ACCESSWIRE / July 31, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Iron Mountain Inc. (NYSE: IRM), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=IRM. The storage and information management services Company announced on July 28, 2017 to acquire Mag Datacenters LLC, operator of Denver private data center business, FORTRUST, for approximately $128 million. FORTRUST is a leading provider of multi-tenant data center space in the Colorado/Mountain region. For immediate access to our complimentary reports, including today’s coverage, register for free now at:

http://protraderdaily.com/register/

Discover more of our free reports coverage from other companies within the Business Software & Services industry. Pro-TD has currently selected Automatic Data Processing, Inc. (NASDAQ: ADP) for due-diligence and potential coverage as the Company announced on July 27, 2017, its financial results for Q4 FY17 and FY17, and also provided its fiscal 2018 outlook. Tune into our site to register for a free membership, and be among the early birds that get our report on Automatic Data Processing when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on IRM; also brushing on ADP. Go directly to your stock of interest and access today’s free coverage at:

http://protraderdaily.com/optin/?symbol=IRM

http://protraderdaily.com/optin/?symbol=ADP

Terms of the Transaction

The transaction, which is subject to customary closing conditions, is expected to close prior to the end of Q3 2017.
Iron Mountain is planning to fund the acquisition with a combination of approximately $73.5 million from a private placement of stock to the seller and $54.5 million in cash. The stock will be unregistered and subject to restrictions on resale under Rule 144 of the Securities Act.
Stabilized return in the mid teens following build-out and lease-up of the expansion capacity is projected.
The Company expects earnings per share dilution of $0.01 to $0.02 in 2017 and for the acquisition to be accretive in 2019 following integration.

Benefits of the Transaction

Expansion Potential within FORTRUST’s Existing Facility: Following the acquisition, Iron Mountain will get an expansion potential within FORTRUST’s existing facility of approximately 38,000 rentable square feet of colocation space that will support another 7 MW of high-density capacity. As of June 30, 2017, FORTRUST’s data center operations comprised a state-of-the-art facility totaling 210,000 square feet of space, including 71,000 rentable square feet of colocation space. The existing space provides about 9 MW of power capacity, 75% of which is leased to a diversified base of 250 customers.

Capacity Increment to more than 30 MW: Mark Kidd, Senior Vice President and General Manager of Iron Mountain Data Centers stated that with this acquisition, the Company will expand its network to better serve target customers for whom Iron Mountain’s reputation for enhanced security, customer service and compliance are important factors in data center selection. This acquisition, together with Phase-I of the Company’s northern Virginia campus will bring total capacity to more than 30 MW with the ability to expand to more than 70 MW across its data center properties.
Access to Larger Portfolio of Locations: Steven Knudson, Chief Executive Officer of FORTRUST stated that the transaction gives customers access to a larger portfolio of locations and services while still receiving the highest level of customer service and operational quality FORTRUST has delivered for over 15 years.
Accelerate Growth in Adjacent Businesses: Iron Mountain President and Chief Executive Officer, William L. Meaney, said that the Company continues to see opportunities to expand its business through strong organic growth, new development, and acquisition. Together with the existing data centers and completion of the first phase of Northern Virginia data center campus next month, this acquisition will strengthen the foundation of a long-term growth engine and help accelerate the growth in Iron Mountain’s adjacent businesses.

About Iron Mountain Inc.

Founded in 1951, Iron Mountain is the global leader for storage and information management services, boasting a real estate network of more than 85 million square feet across more than 1,400 facilities in 52 countries. Iron Mountain’s solutions portfolio includes records management, data management, document management, data centers, art storage and logistics, and secure shredding to help organizations to lower storage costs, comply with regulations, recover from disaster, and better use their information.

Last Close Stock Review

On Friday, July 28, 2017, the stock closed the trading session at $35.19, climbing 1.24% from its previous closing price of $34.76. A total volume of 1.75 million shares have exchanged hands, which was higher than the 3-month average volume of 1.08 million shares. Iron Mountain’s stock price advanced 1.35% in the last one month and 1.24% in the past three months. Furthermore, since the start of the year, shares of the Company have gained 8.34%. The stock is trading at a PE ratio of 96.94 and has a dividend yield of 6.25%. The stock currently has a market cap of $9.18 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 470036